Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Evaluation of G2013 (Α-L-Guluronic Acid) Efficacy on Pc-3 Cells Through Inhibiting the Expression of Inflammatory Factors Publisher Pubmed



Bagherian Z1 ; Mirshafiey A2 ; Mohsenzadegan M3 ; Farajollahi MM1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

Source: Clinical and Experimental Pharmacology and Physiology Published:2022


Abstract

Given multiple treatment strategies for prostate cancer, its mortality rate is still high; therefore, novel treatment strategies seem necessary. G2013 or α-L-guluronic acid is a new patented drug with immunomodulatory and anti-inflammatory properties. This study aimed to evaluate the property of G2013 on inflammatory molecules involved in tumorigenesis of prostate cancer. MTT assay was used to assess the effect of the drug on the proliferation of PC-3 cells. Expression of interleukin 8 (IL-8), Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), myeloid differentiation factor 88 (MYD-88), cyclooxygenase 2 (COX-2), matrix metalloproteinase-2 (MMP-2), and MMP-9 genes were studied in the PC-3 cells treated with 25 (low dose) or 50 (high dose) µg/mL of G2013 for 24 h using quantitative real-time polymerase chain reaction (qRT-PCR) technique. Protein expression of NF-κB and protein activities of MMP-2 and MMP-9 were assayed using flow cytometry and gelatin zymography, respectively. The expression of COX-2 (p = 0.007 at low dose), MMP-2 (p = 0.023 at low dose, p = 0.002 at high dose), NF-κB (p = 0.004 at low dose) and IL-8 (p < 0.0001 in both doses) genes, NF-κB protein (p < 0.0001 in both doses), and MMP-2 activity (p < 0.0001 in both doses) were significantly reduced in the presence of G2013 as compared to the control group. Cancer cell proliferation was also inhibited under 10–500 µg/mL G2013 treatment. Our results revealed that G2013 has the potential to inhibit PC-3 cell proliferation and reduce the expression of tumour-promoting mediators, COX-2, MMP-2, NF-κB, and IL-8 involved in the progression and metastasis of prostate cancer. © 2021 John Wiley & Sons Australia, Ltd
Related Docs
View other Related Docs
1. The Application of G2013 (Α-L-Guluronic Acid) As an Anti-Inflammatory Drug Candidate in Treatment of Disease, Journal of Isfahan Medical School (2021)
2. The Evaluation of Safety Property and Apoptotic Efficacy of Α-L-Guluronic Acid (G2013), As a Novel Nsaid, Under in Vitro Examination on L929 and Hepatocellular Carcinoma Cell Lines, Recent Advances in Inflammation and Allergy Drug Discovery (2021)
3. The Open, Randomized, Positive Control Clinical Trial of Guluronic Acid (G2013) on Sars-Cov-2 Patients, Current Drug Discovery Technologies (2023)
4. Pivotal Cytokines and Their Transcription Factors Are the Targets of Guluronic Acid (G2013) for Inhibiting the Immunopathogenesis Process of Multiple Sclerosis, Drug Development Research (2020)
5. The Effects of Guluronic Acid (G2013), a New Emerging Treatment, on Inflammatory Factors in Nonalcoholic Steatohepatitis Patients Under in Vitro Conditions, Immunopharmacology and Immunotoxicology (2021)
6. Anti‐Inflammatory and Anti‐Tumor Effects of Α-L-Guluronic Acid (G2013) on Cancer-Related Inflammation in a Murine Breast Cancer Model, Biomedicine and Pharmacotherapy (2018)
7. Evaluation of the Oral Administration of Α-L-Guluronic Acid on Cox-1 and Cox-2 Gene Expression Profile in Ankylosing Spondylitis Patients, Drug Development Research (2021)
8. Assessment of Immunological Profile in Ankylosing Spondylitis Patients Following a Clinical Trial With Guluronic Acid (G2013), As a New Nsaid With Immunomodulatory Properties, Immunologic Research (2019)
Experts (# of related papers)
View all Related Experts
Laleh Sharifi (4)
Fatemeh Atyabi (4)
Other Related Docs
9. A Randomized Clinical Trial for the Assessment of the Efficacy and Safety of Guluronic Acid (G2013) in Patients With Rheumatoid Arthritis, Immunopharmacology and Immunotoxicology (2019)
10. Anti-Diabetic and Angio-Protective Effect of Guluronic Acid (G2013) As a New Nonsteroidal Anti-Inflammatory Drug in the Experimental Model of Diabetes, Endocrine# Metabolic and Immune Disorders - Drug Targets (2020)
11. Anti-Tumor Effect of M2000 (Β-D-Mannuronic Acid) on the Expression of Inflammatory Molecules in the Prostate Cancer Cell, Immunopharmacology and Immunotoxicology (2021)
12. Effect of Guluronic Acid (G2013), As a New Anti-Inflammatory Drug on Gene Expression of Pro-Inflammatory and Anti-Inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients, Iranian Journal of Allergy# Asthma and Immunology (2019)
13. Evaluation of the Acute and 28-Day Sub-Acute Intravenous Toxicity of Α-L-Guluronic Acid (Alg; G2013) in Mice, Drug and Chemical Toxicology (2022)
14. Effects of Guluronic Acid (G2013) on Gene Expression of Tlr2, Tlr4, Myd88, Tnf-Α and Cd52 in Multiple Sclerosis Under in Vitro Conditions, Immunopharmacology and Immunotoxicology (2019)
15. The Immunomodulatory Role of G2013 (Α-L-Guluronic Acid) on the Expression of Tlr2 and Tlr4 in Ht29 Cell Line, Current Drug Discovery Technologies (2019)
16. Dysregulated Mirnas Network in the Critical Covid-19: An Important Clue for Uncontrolled Immunothrombosis/Thromboinflammation, International Immunopharmacology (2022)
17. Evaluation of the Effect of Α-L-Guluronic Acid (G2013) on Cox-1, Cox-2 Activity and Gene Expression for Introducing This Drug As a Novel Nsaid With Immunomodulatory Property, Recent Patents on Inflammation and Allergy Drug Discovery (2018)
18. The Effects of G2013 (Α-L-Guluronic Acid) in a Pentylenetetrazole-Induced Kindling Animal Model of Epilepsy, Innovations in Clinical Neuroscience (2020)
19. Effects of Guluronic Acid, As a New Nsaid With Immunomodulatory Properties on Il-17, Rorγt, Il-4 and Gata-3 Gene Expression in Rheumatoid Arthritis Patients, Immunopharmacology and Immunotoxicology (2020)
20. The Safety and Efficacy of Guluronic Acid (G2013) in Ankylosing Spondylitis: A Randomized Controlled Parallel Clinical Trial, Pharmacological Reports (2019)
21. Effects of Guluronic Acid (G2013) on Ship1, Socs1 Induction and Related Molecules in Tlr4 Signaling Pathway, International Immunopharmacology (2018)
22. Immunomodulatory Effect of G2013 (Α-L-Guluronic Acid) on the Tlr2 and Tlr4 in Human Mononuclear Cells, Current Drug Discovery Technologies (2018)
23. Antagonistic Property of G2013 (Α-L-Guluronic Acid) on Gene Expression of Myd88, Tollip, and Nf-Κb in Hek293 Tlr2 and Hek293 Tlr4, Endocrine# Metabolic and Immune Disorders - Drug Targets (2019)
24. Anti-Inflammatory Property of Β-D-Mannuronic Acid (M2000) on Expression and Activity of Matrix Metalloproteinase-2 and -9 Through Cd147 Molecule in Phorbol Myristate Acetate-Differentiated Thp-1 Cells, Iranian Journal of Allergy# Asthma and Immunology (2017)
25. Anti-Multispecies Microbial Biofilms and Anti-Inflammatory Effects of Antimicrobial Photo-Sonodynamic Therapy Based on Acrylic Resin Containing Nano-Resveratrol, Photodiagnosis and Photodynamic Therapy (2023)
26. Expression Analysis of Nf-Κb-Associated Long Noncoding Rnas in Peripheral Blood Mononuclear Cells From Relapsing-Remitting Multiple Sclerosis Patients, Journal of Neuroimmunology (2021)
27. Concomitant Blockade of A2ar and Ctla-4 by Sirna-Loaded Polyethylene Glycol-Chitosan-Alginate Nanoparticles Synergistically Enhances Antitumor T-Cell Responses, Journal of Cellular Physiology (2020)
28. Simultaneous Inhibition of Cd73 and Il-6 Molecules by Sirna-Loaded Nanoparticles Prevents the Growth and Spread of Cancer, Nanomedicine: Nanotechnology# Biology# and Medicine (2021)
29. Resveratrol in Breast Cancer Treatment: From Cellular Effects to Molecular Mechanisms of Action, Cellular and Molecular Life Sciences (2022)
30. An in Vitro Evaluation of Anti-Aging Effect of Guluronic Acid (G2013) Based on Enzymatic Oxidative Stress Gene Expression Using Healthy Individuals Pbmcs, Biomedicine and Pharmacotherapy (2017)
31. Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy, Nanomedicine: Nanotechnology# Biology# and Medicine (2020)
32. The Role of Cxc Chemokines and Receptors in Breast Cancer, Clinical and Experimental Medicine (2025)
33. A Novel Inflammatory Signaling Pathway in Patients With Slow Coronary Flow: Nf-Κb/Il-1Β/Nitric Oxide, Cytokine (2021)
34. Modulation of Macrophage Polarization for Bone Tissue Engineering Applications, Iranian Journal of Allergy# Asthma and Immunology (2018)
35. Effect of Curcumin on the Expression of Nod2 Receptor and Pro-Inflammatory Cytokines in Fibroblast-Like Synoviocytes (Flss) of Rheumatoid Arthritis (Ra) Patients, Advances in Rheumatology (2023)
36. Inhibition of Cd73 Using Folate Targeted Nanoparticles Carrying Anti-Cd73 Sirna Potentiates Anticancer Efficacy of Dinaciclib, Life Sciences (2020)
37. A Randomized, Controlled, Phase Ii Clinical Trial of Β-D-Mannuronic Acid (M2000) in Pre-Surgical Breast Cancer Patients at Early Stage (T1-T2), Clinical and Experimental Pharmacology and Physiology (2019)
38. A Review on the Role of M2 Macrophages in Bladder Cancer; Pathophysiology and Targeting, International Immunopharmacology (2019)
39. Combined Inhibition of Cd73 and Zeb1 by Arg-Gly-Asp (Rgd)-Targeted Nanoparticles Inhibits Tumor Growth, Colloids and Surfaces B: Biointerfaces (2021)
40. Anti-Biofilm and Bystander Effects of Antimicrobial Photo-Sonodynamic Therapy Against Polymicrobial Periopathogenic Biofilms Formed on Coated Orthodontic Mini-Screws With Zinc Oxide Nanoparticles, Photodiagnosis and Photodynamic Therapy (2023)
41. The Anti-Tumoral Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid on Treg Cells Frequency and Mmp-2, Mmp-9, Ccl22 and Tgfβ1 Gene Expression in Pre-Surgical Breast Cancer Patients, Iranian Journal of Allergy# Asthma and Immunology (2019)